DUBLIN--(BUSINESS WIRE)--
ICON
plc. (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider
of outsourced development services to the pharmaceutical, biotechnology
and medical device industries, today announced that Dr. Bruce Given,
non-executive chairman of the board, has notified the company that it is
his intention not to seek a second term as chairman when his current
term expires on December 31st 2012. Dr. Given has served as
ICON's chairman since 1st January 2010 and has been a member
of the company's board of directors since 2004.
Dr. Given commented, "The time commitment for the chairman's role
was increasingly challenging given my operational responsibilities
outside of ICON. Having overseen a very successful transition in the
executive leadership of the company, new strategic alliances, as well as
a return to strong growth in revenues and earnings, I believe the timing
is right for me to relinquish the chair."
On behalf of the board, Mr. Ciaran Murray, ICON CEO, commented, "I
would like to thank Bruce for his leadership and support over the past
three years in his role as chairman."
The board of directors will now initiate a process to select a new
chairman, from among its members, to be appointed with effect from
January 1st 2013.
The information contained in this release is as of 29th
November 2012. The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to ICON
and its business can be found in ICON's
Annual Report for the fiscal year ended December 31, 2011 and in the
forms filed with the US
Securities and Exchange Commission, including the Forms 20-F, F-1,
S-8 and F-3. ICON disclaims any intent or obligation to update these
forward-looking statements.
About ICON plc:
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 82 locations in 40 countries and
has approximately 9,430 employees. Further information is available at www.iconplc.com.
ICON/ICLR-F
Investor Relations
1-888-381-7923
or
Brendan Brennan
Chief
Financial Officer
+ 353 —1-291-2000
or
Sam Farthing
VP
Investor Relations
+ 353 —1-291-2000
All at ICON.
Source: ICON plc
News Provided by Acquire Media
